Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 15, 2015, Pages 6225-6236

  Priestley, E Scott ^a   Cheney, Daniel L ^a   DeLucca, Indawati ^a   Wei, Anzhi ^a   Luettgen, Joseph M ^a   Rendina, Alan R ^a   Wong, Pancras C ^a   Wexler, Ruth R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL GROUP; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; MACROCYCLIC COMPOUND; METHYL GROUP; PYRROLIDINE DERIVATIVE; SERINE PROTEINASE; SULFONE DERIVATIVE; SERINE PROTEINASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; MOLECULAR MODEL; PROTHROMBIN TIME; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY;

DRUG DESIGN; FACTOR VIIA; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SERINE PROTEINASE INHIBITORS;

EID: 84939175053     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00788     Document Type: Article

References (76)

1. Mackman, N.; Tilley, R. E.; Key, N. S. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis Arterioscler., Thromb., Vasc. Biol. 2007, 27, 1687-1693 10.1161/ATVBAHA.107.141911
2. Banner, D. W.; D'Arcy, A.; Chene, C.; Winkler, F. K.; Guha, A.; Konigsberg, W. H.; Nemerson, Y.; Kirchhofer, D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor Nature 1996, 380, 41-46 10.1038/380041a0
3. Harker, L. A.; Hanson, S. R.; Wilcox, J. N.; Kelly, A. B. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway Pathophysiol. Haemostasis Thromb. 1996, 26 (Suppl. 1) 76-82 10.1159/000217245
4. Golino, P.; Ragni, M.; Cirillo, P.; D'Andrea, D.; Scognamiglio, A.; Ravera, A.; Buono, C.; Ezban, M.; Corcione, N.; Vigorito, F.; Condorelli, M.; Chiariello, M. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis Circ. Res. 1998, 82, 39-46 10.1161/01.RES.82.1.39
5. Suleymanov, O. D.; Szalony, J. A.; Salyers, A. K.; Lachance, R. M.; Parlow, J. J.; South, M. S.; Wood, R. S.; Nicholson, N. S. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model J. Pharmacol. Exp. Ther. 2003, 306, 1115-1121 10.1124/jpet.103.052779
6. Szalony, J. A.; Suleymanov, O. D.; Salyers, A. K.; Panzer-Knodle, S. G.; Blom, J. D.; LaChance, R. M.; Case, B. L.; Parlow, J. J.; South, M. S.; Wood, R. S.; Nicholson, N. S. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time Thromb. Res. 2003, 112, 167-174 10.1016/j.thromres.2003.10.017
7. Salyers, A. K.; Szalony, J. A.; Suleymanov, O. D.; Parlow, J. J.; Wood, R. S.; South, M. S.; Nicholson, N. S. Assessment of bleeding propensity in non-human primates by combination of selective tissue factor/VIIa inhibition and aspirin compared to warfarin and aspirin treatment Pharmacology 2004, 70, 100-106 10.1159/000074674
8. Olivero, A. G.; Eigenbrot, C.; Goldsmith, R.; Robarge, K.; Artis, D. R.; Flygare, J.; Rawson, T.; Sutherlin, D. P.; Kadkhodayan, S.; Beresini, M.; Elliott, L. O.; DeGuzman, G. G.; Banner, D. W.; Ultsch, M.; Marzec, U.; Hanson, S. R.; Refino, C.; Bunting, S.; Kirchhofer, D. A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo J. Biol. Chem. 2005, 280, 9160-9169 10.1074/jbc.M409068200
9. Young, W. B.; Mordenti, J.; Torkelson, S.; Shrader, W. D.; Kolesnikov, A.; Rai, R.; Liu, L.; Hu, H.; Leahy, E. M.; Green, M. J.; Sprengeler, P. A.; Katz, B. A.; Yu, C.; Janc, J. W.; Elrod, K. C.; Marzec, U. M.; Hanson, S. R. Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model Bioorg. Med. Chem. Lett. 2006, 16, 2037-2041 10.1016/j.bmcl.2005.12.059
10. Zbinden, K. G.; Banner, D. W.; Hilpert, K.; Himber, J.; Lave, T.; Riederer, M. A.; Stahl, M.; Tschopp, T. B.; Obst-Sander, U. Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity Bioorg. Med. Chem. 2006, 14, 5357-5369 10.1016/j.bmc.2006.03.042
11. Arnold, C. S.; Parker, C.; Upshaw, R.; Prydz, H.; Chand, P.; Kotian, P.; Bantia, S.; Babu, Y. S. The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor Thromb. Res. 2006, 117, 343-349 10.1016/j.thromres.2005.03.015
12. Wong, P. C.; Luettgen, J. M.; Rendina, A. R.; Kettner, C. A.; Xin, B.; Knabb, R. M.; Wexler, R. R.; Priestley, E. S. BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihemostatic studies Thromb. Haemostasis 2010, 104, 261-269 10.1160/TH10-01-0025
13. Lee, A.; Agnelli, G.; Buller, H.; Ginsberg, J.; Heit, J.; Rote, W.; Vlasuk, G.; Costantini, L.; Julian, J.; Comp, P.; van der Meer, J.; Piovella, F.; Raskob, G.; Gent, M. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement Circulation 2001, 104, 74-78 10.1161/hc2601.091386
14. Moons, A. H. M.; Peters, R. J. G.; Bijsterveld, N. R.; Piek, J. J.; Prins, M. H.; Vlasuk, G. P.; Rote, W. E.; Buller, H. R. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty J. Am. Coll. Cardiol. 2003, 41, 2147-2153 10.1016/S0735-1097(03)00478-9
15. Giugliano, R. P.; Wiviott, S. D.; Stone, P. H.; Simon, D. I.; Schweiger, M. J.; Bouchard, A.; Leesar, M. A.; Goulder, M. A.; Deitcher, S. R.; McCabe, C. H.; Braunwald, E. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial J. Am. Coll. Cardiol. 2007, 49, 2398-407 10.1016/j.jacc.2007.02.065
16. Young, W. B.; Kolesnikov, A.; Rai, R.; Sprengeler, P. A.; Leahy, E. M.; Shrader, W. D.; Sangalang, J.; Burgess-Henry, J.; Spencer, J.; Elrod, K.; Cregar, L. Optimization of a screening lead for factor VIIa/TF Bioorg. Med. Chem. Lett. 2001, 11, 2253-2256 10.1016/S0960-894X(01)00420-6
17. Riggs, J. R.; Kolesnikov, A.; Hendrix, J.; Young, W. B.; Shrader, W. D.; Vijaykumar, D.; Stephens, R.; Liu, L.; Pan, L.; Mordenti, J.; Green, M. J.; Sukbuntherng, J. Factor VIIa inhibitors: A prodrug strategy to improve oral bioavailability Bioorg. Med. Chem. Lett. 2006, 16, 2224-2228 10.1016/j.bmcl.2006.01.039
18. Kolesnikov, A.; Rai, R.; Young, W. B.; Mordenti, J.; Liu, L.; Torkelson, S.; Shrader, W. D.; Leahy, E. M.; Hu, H.; Gjerstad, E.; Janc, J.; Katz, B. A.; Sprengeler, P. A. Factor VIIa inhibitors: improved pharmacokinetic parameters Bioorg. Med. Chem. Lett. 2006, 16, 2243-2246 10.1016/j.bmcl.2006.01.037
19. Rai, R.; Kolesnikov, A.; Sprengeler, P. A.; Torkelson, S.; Ton, T.; Katz, B. A.; Yu, C.; Hendrix, J.; Shrader, W. D.; Stephens, R.; Cabuslay, R.; Sanford, E.; Young, W. B. Discovery of novel heterocyclic factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 2270-2273 10.1016/j.bmcl.2006.01.017
20. Riggs, J. R.; Hu, H.; Kolesnikov, A.; Leahy, E. M.; Wesson, K. E.; Shrader, W. D.; Vijaykumar, D.; Wahl, T. A.; Tong, Z.; Sprengeler, P. A.; Green, M. J.; Yu, C.; Katz, B. A.; Sanford, E.; Nguyen, M.; Cabuslay, R.; Young, W. B. Novel 5-azaindole factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 3197-3200 10.1016/j.bmcl.2006.03.049
21. Vijaykumar, D.; Rai, R.; Shaghafi, M.; Ton, T.; Torkelson, S.; Leahy, E. M.; Riggs, J. R.; Hu, H.; Sprengeler, P. A.; Shrader, W. D.; O'Bryan, C.; Cabuslay, R.; Sanford, E.; Gjerstadt, E.; Liu, L.; Sukbuntherng, J.; Young, W. B. Efforts toward oral bioavailability in factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 3829-3832 10.1016/j.bmcl.2006.04.018
22. Hu, H.; Kolesnikov, A.; Riggs, J. R.; Wesson, K. E.; Stephens, R.; Leahy, E. M.; Shrader, W. D.; Sprengeler, P. A.; Green, M. J.; Sanford, E.; Nguyen, M.; Gjerstad, E.; Cabuslay, R.; Young, W. B. Potent 4-amino-5-azaindole factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 4567-4570 10.1016/j.bmcl.2006.06.016
23. Groebke Zbinden, K.; Banner, D. W.; Ackermann, J.; D'Arcy, A.; Kirchhofer, D.; Ji, Y.-H.; Tschopp, T. B.; Wallbaum, S.; Weber, L. Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 817-822 10.1016/j.bmcl.2004.10.092
24. Zbinden, K. G.; Obst-Sander, U.; Hilpert, K.; Kuehne, H.; Banner, D. W.; Boehm, H.-J.; Stahl, M.; Ackermann, J.; Alig, L.; Weber, L.; Wessel, H. P.; Riederer, M. A.; Tschopp, T. B.; Lave, T. Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 5344-5352 10.1016/j.bmcl.2005.04.079
25. Glunz, P. W.; Zhang, X.; Zou, Y.; Delucca, I.; Nirschl, A. H.; Cheng, X.; Weigelt, C. A.; Cheney, D. L.; Wei, A.; Anumula, R.; Luettgen, J. M.; Rendina, A. R.; Harpel, M.; Luo, G.; Knabb, R.; Wong, P. C.; Wexler, R. R.; Priestley, E. S. Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 5244-5248 10.1016/j.bmcl.2013.06.027
26. Zhang, X.; Jiang, W.; Jacutin-Porte, S.; Glunz, P. W.; Zou, Y.; Cheng, X.; Nirschl, A. H.; Wurtz, N. R.; Luettgen, J. M.; Rendina, A. R.; Luo, G.; Harper, T. M.; Wei, A.; Anumula, R.; Cheney, D. L.; Knabb, R. M.; Wong, P. C.; Wexler, R. R.; Priestley, E. S. Design and synthesis of phenylpyrrolidine phenylglycinamides as highly potent and selective TF-FVIIA inhibitors ACS Med. Chem. Lett. 2014, 5, 188-192 10.1021/ml400453z
27. South, M. S.; Case, B. L.; Wood, R. S.; Jones, D. E.; Hayes, M. J.; Girard, T. J.; Lachance, R. M.; Nicholson, N. S.; Clare, M.; Stevens, A. M.; Stegeman, R. A.; Stallings, W. C.; Kurumbail, R. G.; Parlow, J. J. Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex Bioorg. Med. Chem. Lett. 2003, 13, 2319-2325 10.1016/S0960-894X(03)00410-4
28. Parlow, J. J.; Case, B. L.; Dice, T. A.; Fenton, R. L.; Hayes, M. J.; Jones, D. E.; Neumann, W. L.; Wood, R. S.; Lachance, R. M.; Girard, T. J.; Nicholson, N. S.; Clare, M.; Stegeman, R. A.; Stevens, A. M.; Stallings, W. C.; Kurumbail, R. G.; South, M. S. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex J. Med. Chem. 2003, 46, 4050-4062 10.1021/jm030131l
29. Parlow, J. J.; Kurumbail, R. G.; Stegeman, R. A.; Stevens, A. M.; Stallings, W. C.; South, M. S. Design, synthesis, and crystal structure of selective 2-pyridone tissue factor VIIa inhibitors J. Med. Chem. 2003, 46, 4696-4701 10.1021/jm0301686
30. Schweitzer, B. A.; Neumann, W. L.; Rahman, H. K.; Kusturin, C. L.; Sample, K. R.; Poda, G. I.; Kurumbail, R. G.; Stevens, A. M.; Stegeman, R. A.; Stallings, W. C.; South, M. S. Structure-based design and synthesis of pyrazinones containing novel P1 'side pocket' moieties as inhibitors of TF/VIIa Bioorg. Med. Chem. Lett. 2005, 15, 3006-3011 10.1016/j.bmcl.2005.04.037
31. Zhang, X.; Glunz, P. W.; Jiang, W.; Schmitt, A.; Newman, M.; Barbera, F. A.; Bozarth, J. M.; Rendina, A. R.; Wei, A.; Wen, X.; Rossi, K. A.; Luettgen, J. M.; Wong, P. C.; Knabb, R. M.; Wexler, R. R.; Priestley, E. S. Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 1604-1607 10.1016/j.bmcl.2013.01.094
32. Priestley, E. S.; DeLucca, I.; Zhou, J.; Zhou, J.; Saiah, E.; Stanton, R.; Robinson, L.; Luettgen, J. M.; Wei, A.; Wen, X.; Knabb, R. M.; Wong, P. C.; Wexler, R. R. Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor Bioorg. Med. Chem. Lett. 2013, 23, 2432-2435 10.1016/j.bmcl.2013.02.013
33. Kohrt, J. T.; Filipski, K. J.; Cody, W. L.; Cai, C.; Dudley, D. A.; Van Huis, C. A.; Willardsen, J. A.; Rapundalo, S. T.; Saiya-Cork, K.; Leadley, R. J.; Narasimhan, L.; Zhang, E.; Whitlow, M.; Adler, M.; McLean, K.; Chou, Y.-L.; McKnight, C.; Arnaiz, D. O.; Shaw, K. J.; Light, D. R.; Edmunds, J. J. The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex Bioorg. Med. Chem. Lett. 2005, 15, 4752-4756 10.1016/j.bmcl.2005.07.059
34. Kohrt, J. T.; Filipski, K. J.; Cody, W. L.; Cai, C.; Dudley, D. A.; Van Huis, C. A.; Willardsen, J. A.; Narasimhan, L. S.; Zhang, E.; Rapundalo, S. T.; Saiya-Cork, K.; Leadley, R. J.; Edmunds, J. J. The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex-Part 2 Bioorg. Med. Chem. Lett. 2006, 16, 1060-1064 10.1016/j.bmcl.2005.10.076
35. Klingler, O.; Matter, H.; Schudok, M.; Bajaj, S. P.; Czech, J.; Lorenz, M.; Nestler, H. P.; Schreuder, H.; Wildgoose, P. Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2003, 13, 1463-1467 10.1016/S0960-894X(03)00168-9
36. Klingler, O.; Matter, H.; Schudok, M.; Donghi, M.; Czech, J.; Lorenz, M.; Nestler, H. P.; Szillat, H.; Schreuder, H. Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition Bioorg. Med. Chem. Lett. 2004, 14, 3715-3720 10.1016/j.bmcl.2004.05.006
37. Kohrt, J. T.; Filipski, K. J.; Rapundalo, S. T.; Cody, W. L.; Edmunds, J. J. An efficient synthesis of 2-[3-(4-amidinophenylcarbamoyl)naphthalen-2-yl]-5-[(2,2-methylpropyl)carbamoyl]benzoic acid: a factor VIIa inhibitor discovered by the Ono Pharmaceutical Company Tetrahedron Lett. 2000, 41, 6041-6044 10.1016/S0040-4039(00)01016-9
38. Miura, M.; Seki, N.; Koike, T.; Ishihara, T.; Niimi, T.; Hirayama, F.; Shigenaga, T.; Sakai-Moritani, Y.; Kawasaki, T.; Sakamoto, S.; Okada, M.; Ohta, M.; Tsukamoto, S.-I. Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand Bioorg. Med. Chem. 2006, 14, 7688-7705 10.1016/j.bmc.2006.08.010
39. Miura, M.; Seki, N.; Koike, T.; Ishihara, T.; Niimi, T.; Hirayama, F.; Shigenaga, T.; Sakai-Moritani, Y.; Tagawa, A.; Kawasaki, T.; Sakamoto, S.; Okada, M.; Ohta, M.; Tsukamoto, S.-i. Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands Bioorg. Med. Chem. 2007, 15, 160-173 10.1016/j.bmc.2006.09.071
40. Kotian, P. L.; Krishnan, R.; Rowland, S.; El-Kattan, Y.; Saini, S. K.; Upshaw, R.; Bantia, S.; Arnold, S.; Sudhakar, B. Y.; Chand, P. Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores Bioorg. Med. Chem. 2009, 17, 3934-3958 10.1016/j.bmc.2009.04.013
41. Bolton, S. A.; Sutton, J. C.; Anumula, R.; Bisacchi, G. S.; Jacobson, B.; Slusarchyk, W. A.; Treuner, U. D.; Wu, S. C.; Zhao, G.; Pi, Z.; Sheriff, S.; Smirk, R. A.; Bisaha, S.; Cheney, D. L.; Wei, A.; Schumacher, W. A.; Hartl, K. S.; Liu, E.; Zahler, R.; Seiler, S. M. Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold Bioorg. Med. Chem. Lett. 2013, 23, 5239-5243 10.1016/j.bmcl.2013.06.028
42. Sagi, K.; Fujita, K.; Sugiki, M.; Takahashi, M.; Takehana, S.; Tashiro, K.; Kayahara, T.; Yamanashi, M.; Fukuda, Y.; Oono, S.; Okajima, A.; Iwata, S.; Shoji, M.; Sakurai, K. Optimization of a coagulation factor VIIa inhibitor found in factor Xa inhibitor library Bioorg. Med. Chem. 2005, 13, 1487-1496 10.1016/j.bmc.2004.12.033
43. Glunz, P. W.; Cheng, X.; Cheney, D. L.; Weigelt, C. A.; Wei, A.; Luettgen, J. M.; Wong, P. C.; Wexler, R. R.; Priestley, E. S. Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors Bioorg. Med. Chem. Lett. 2015, 25, 2169-2173 10.1016/j.bmcl.2015.03.062
44. Priestley, E. S. Tissue factor-fVIIa inhibition: update on an unfinished quest for a novel oral antithrombotic Drug Discovery Today 2014, 19, 1440-1444 10.1016/j.drudis.2014.05.023
45. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain Biochem. Biophys. Res. Commun. 1967, 27, 157-62 10.1016/S0006-291X(67)80055-X
46. Cheney, D. L.; Bozarth, J. M.; Metzler, W. J.; Morin, P. E.; Mueller, L.; Newitt, J. A.; Nirschl, A. H.; Rendina, A. R.; Tamura, J. K.; Wei, A.; Wen, X.; Wurtz, N. R.; Seiffert, D. A.; Wexler, R. R.; Priestley, E. S. Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening J. Med. Chem. 2015, 58, 2799-2808 10.1021/jm501982k
47. Quan, M. L.; Wexler, R. R. The design and synthesis of noncovalent Factor Xa inhibitors Curr. Top. Med. Chem. 2001, 1, 137-149 10.2174/1568026013395407
48. Lam, P. Y. S.; Clark, C. G.; Li, R.; Pinto, D. J. P.; Orwat, M. J.; Galemmo, R. A.; Fevig, J. M.; Teleha, C. A.; Alexander, R. S.; Smallwood, A. M.; Rossi, K. A.; Wright, M. R.; Bai, S. A.; He, K.; Luettgen, J. M.; Wong, P. C.; Knabb, R. M.; Wexler, R. R. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants J. Med. Chem. 2003, 46, 4405-4418 10.1021/jm020578e
49. Pinto, D. J. P.; Galemmo, R. A.; Quan, M. L.; Orwat, M. J.; Clark, C.; Li, R.; Wells, B.; Woerner, F.; Alexander, R. S.; Rossi, K. A.; Smallwood, A.; Wong, P. C.; Luettgen, J. M.; Rendina, A. R.; Knabb, R. M.; He, K.; Wexler, R. R.; Lam, P. Y. S. Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties Bioorg. Med. Chem. Lett. 2006, 16, 5584-5589 10.1016/j.bmcl.2006.08.027
50. Jackson, S.; DeGrado, W.; Dwivedi, A.; Parthasarathy, A.; Higley, A.; Krywko, J.; Rockwell, A.; Markwalder, J.; Wells, G. et al. Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPIIb/IIIa J. Am. Chem. Soc. 1994, 116, 3220-30 10.1021/ja00087a007
51. Cherney, R. J.; Wang, L.; Meyer, D. T.; Xue, C. B.; Wasserman, Z. R.; Hardman, K. D.; Welch, P. K.; Covington, M. B.; Copeland, R. A.; Arner, E. C.; DeGrado, W. F.; Decicco, C. P. Macrocyclic amino carboxylates as selective MMP-8 inhibitors J. Med. Chem. 1998, 41, 1749-51 10.1021/jm970850y
52. Kim, Y.-K.; Arai, M. A.; Arai, T.; Lamenzo, J. O.; Dean, E. F., III; Patterson, N.; Clemons, P. A.; Schreiber, S. L. Relationship of Stereochemical and Skeletal Diversity of Small Molecules to Cellular Measurement Space J. Am. Chem. Soc. 2004, 126, 14740-14745 10.1021/ja048170p
53. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery-an underexploited structural class Nat. Rev. Drug Discovery 2008, 7, 608-24 10.1038/nrd2590
54. Marsault, E.; Peterson, M. L. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery J. Med. Chem. 2011, 54, 1961-2004 10.1021/jm1012374
55. Vendeville, S.; Cummings, M. D. Synthetic macrocycles in small-molecule drug discovery Annu. Rep. Med. Chem. 2013, 48, 371-386 10.1016/B978-0-12-417150-3.00023-5
56. Giordanetto, F.; Kihlberg, J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 2014, 57, 278-95 10.1021/jm400887j
57. Macias, J.; Neukam, K.; Merchante, N.; Pineda, J. A. Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients Expert Opin. Pharmacother. 2014, 15, 1837-1848 10.1517/14656566.2014.934810
58. Discover-3; Accelrys, Inc.: San Diego, CA.
59. TURBOMOLE, version 6.2 (a development of University of Karlsruhe and Forschungszentrum Karlsruhe GmbH, 1989-2007); TURBOMOLE GmbH (since 2007): Karlsruhe, Germany, 2010; http://www.turbomole.com.
60. COSMOtherm, version C3.0, revision 13.01; COSMOlogic GmbH & Co. KG (Imbacher Weg 46, 51379, Leverkusen Germany).
61. Petasis, N. A.; Goodman, A.; Zavialov, I. A. A new synthesis of α-arylglycines from aryl boronic acids Tetrahedron 1997, 53, 16463-16470 10.1016/S0040-4020(97)01028-4
62. Ishiyama, T.; Murata, M.; Miyaura, N. Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters J. Org. Chem. 1995, 60, 7508-10 10.1021/jo00128a024
63. Brown, H. C.; Prasad, J. V. N. V. Chiral synthesis via organoboranes. 9. Crystalline chelates from borinic and boronic esters. A simple procedure for upgrading borinates and boronates to materials approaching 100% optical purity J. Org. Chem. 1986, 51, 4526-30 10.1021/jo00374a007
64. Esteban, G.; Lopez-Sanchez, M. A.; Martinez, M. E.; Plumet, J. A convenient procedure for the synthesis of 1-tetralone derivatives using a Suzuki coupling-Friedel-Crafts acylation sequence Tetrahedron 1998, 54, 197-212 10.1016/S0040-4020(97)10270-8
65. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology; Academic Press, Inc.: New York, NY, 1997; Vol. 276 (Macromolecular Crystallography part A), pp 307-326.
66. Brünger, A. T.; Kuriyan, J.; Karplus, M. Crystallographic R factor refinement by molecular dynamics Science 1987, 235, 458-460 10.1126/science.235.4787.458
67. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501 10.1107/S0907444910007493
68. Hwang, M. J.; Ni, X.; Waldman, M.; Ewig, C. S.; Hagler, A. T. Derivation of class II force fields. VI. Carbohydrate compounds and anomeric effects Biopolymers 1998, 45, 435-468 10.1002/(SICI)1097-0282(199805)45:6<435::AID-BIP3>3.0.CO;2-Q
69. Maple, J. R.; Hwang, M. J.; Jalkanen, K. J.; Stockfisch, T. P.; Hagler, A. T. Derivation of class II force fields. V. Quantum force field for amides, peptides, and related compounds J. Comput. Chem. 1998, 19, 430-458 10.1002/(SICI)1096-987X(199803)19:4<430::AID-JCC5>3.0.CO;2-T
70. Maple, J. R.; Hwang, M. J.; Stockfisch, T. P.; Hagler, A. T. Derivation of Class II force fields. III. Characterization of a quantum force field for alkanes Isr. J. Chem. 1994, 34, 195-231 10.1002/ijch.199400025
71. Hwang, M. J.; Stockfisch, T. P.; Hagler, A. T. Derivation of Class II Force Fields. 2. Derivation and Characterization of a Class II Force Field, CFF93, for the Alkyl Functional Group and Alkane Molecules J. Am. Chem. Soc. 1994, 116, 2515-25 10.1021/ja00085a036
72. Maple, J. R.; Hwang, M. J.; Stockfisch, T. P.; Dinur, U.; Waldman, M.; Ewig, C. S.; Hagler, A. T. Derivation of Class II force fields. I. Methodology and quantum force field for the alkyl function group and alkane molecules J. Comput. Chem. 1994, 15, 162-82 10.1002/jcc.540150207
73. MacroModel, version 9.0; Schrödinger, LLC: New York, NY, 2005.
74. Liljefors, T.; Bostrom, J.; Norrby, P.-O. Conformational energies of protein-bound ligands. In Rational Molecular Design in Drug Research; Liljefors, T.; Jorgenson, F. S.; Krogsgaard-Larsen, P., Eds.; Alfred Benzon Symposium 42; Munksgaard: Copenhagen, Denmark, 1998; pp 246-263.
75. Bostrom, J.; Norrby, P.-O.; Liljefors, T. Conformational energy penalties of protein-bound ligands J. Comput.-Aided Mol. Des. 1998, 12, 383-396 10.1023/A:1008007507641
76. Jaguar, version 6.0; Schrödinger, LLC: New York, NY, 2005.